As of October 31, more than 460 A-share listed pharmaceutical companies have disclosed their 2022 third quarterly reports, and nearly half
of the companies have achieved growth in the first three quarters.
Among them, 23 pharmaceutical companies had a net profit of more than 2 billion yuan in the first three quarters, including WuXi AppTec, Hengrui Pharmaceutical, Wantai Biologics, Clarion, Renfu Pharmaceutical, etc.
, and the high-light enterprise is Jiuan Medical, which has exceeded 10 billion yuan
in the first three quarters.
Jiuan Medical announced on the evening of October 28 that the company's net profit in the first three quarters was 16.
05 billion yuan, a year-on-year increase of 31918.
64%; Revenue was 24.
589 billion yuan, a year-on-year increase of 3010.
77%.
Among them, the net profit in the third quarter alone was 807 million yuan, a year-on-year increase of 17452.
26%; In the third quarter alone, revenue reached 1.
323 billion yuan, a year-on-year increase of 497.
31%.
For the reason for the large increase in revenue in the first three quarters, the company said that it was mainly due to the significant increase in
kit sales.
Jiuan Medical said, "Due to the significant increase in sales revenue of iHealth kit products during the reporting period, the company's performance also increased
significantly compared with the same period last year.
”
Affected by the sharp increase in performance, Jiuan Medical was directly sent to the price limit
.
On the morning of November 1, Jiuan Medical opened higher, once rising more than 4%.
As of 10:09, the stock rose back to 1.
70% at 48.
50 yuan, with a turnover of 533 million, a turnover rate of 2.
24%, and a price-to-earnings (TTM) of 1.
38
.
In addition to Jiuan Medical, during the reporting period, many leading companies in the industry performed well
.
Among the 23 listed companies with net profit exceeding 2 billion yuan, 17 achieved year-on-year growth, including WuXi AppTec, Wantai Biologics, Mentor Biologics, Anxu Biologics, Kelleying, Renfu Pharmaceutical, BGI, etc.
all doubled
their net profits.
Among them, Anxu Biotechnology, which also benefited from the surge in the sales scale of testing products, achieved operating income of 6.
127 billion yuan in the first three quarters, a year-on-year increase of 798.
35%.
The net profit attributable to shareholders of listed companies was 3.
132 billion yuan, a year-on-year increase of 1003.
25%.
The net profit attributable to the shareholders of the listed company after deducting non-recurring profits and losses was 3.
103 billion yuan, and the basic earnings per share were 34.
51 yuan per share
.
WuXi AppTec and Clarion are both leading CRO enterprises, and the net profits of the two companies in the first three quarters increased by 107.
12% and 291.
58% year-on-year, respectively, highlighting the prosperity of
the pharmaceutical R&D and production outsourcing industry.
Among them, WuXi AppTec also raised its full-year revenue growth target in its third quarterly report, adjusting the previously announced revenue growth target for 2022 from 68-72% to 70-72%, and will also maintain the target
of a compound revenue growth rate of no less than 34% from 2021 to 2024.
However, from the perspective of CRO companies that have disclosed three quarterly reports, not all companies continue to maintain a high-speed growth situation, and there are also many companies in the first three quarters of the net profit attributable to shareholders of listed companies declined, including Price, Boji Pharmaceutical, PharmaBlock Technology, Baihua Pharmaceutical, Tigermed and so on, the growth rate decreased by 13.
04%, 35.
72%, 43.
57%, 79.
97% and 9.
9%
respectively year-on-year.
It can be seen that the performance differentiation of the industry is relatively obvious
.
In addition, Mindray, a leading medical device company, also achieved a good "report card"
in the first three quarters.
The company achieved revenue of 23.
296 billion yuan in the first three quarters, an increase of 20.
1% over the same period of the previous year; The net profit was 8.
102 billion yuan, an increase of 21.
6% over the same period of the previous year, and the net profit has exceeded the whole year
of 2021.
Regarding the reasons for the increase in performance, Mindray said that in the third quarter of 2022, benefiting from the vigorous development of new domestic medical infrastructure and the continuous recovery of global routine business, the company continued to strengthen internal management, continuously improve operating efficiency, and achieve stable and healthy growth in
operating income and net profit.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];